Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110?, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110? and p110?, p110? is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idelalisib. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Idelalisib. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Idelalisib. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idelalisib. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Idelalisib. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Idelalisib. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idelalisib. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idelalisib. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idelalisib. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idelalisib. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Idelalisib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Idelalisib. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Idelalisib. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idelalisib. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Idelalisib. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idelalisib. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Idelalisib. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Idelalisib. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idelalisib. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idelalisib. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Idelalisib. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idelalisib. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Idelalisib. |
| Cladribine | Idelalisib may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Idelalisib. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Idelalisib. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Idelalisib. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Idelalisib. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Idelalisib. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Idelalisib. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Idelalisib. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Idelalisib. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Idelalisib. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Idelalisib. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idelalisib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Idelalisib. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Idelalisib. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Idelalisib. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Idelalisib. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Idelalisib. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Idelalisib. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Idelalisib. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idelalisib. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idelalisib. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idelalisib. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Idelalisib. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Idelalisib. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Idelalisib. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Idelalisib. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Idelalisib. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Idelalisib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Idelalisib. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Idelalisib. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Idelalisib. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Idelalisib. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Idelalisib. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Idelalisib. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idelalisib. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Idelalisib. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Idelalisib. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Idelalisib. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Idelalisib. |
| Thalidomide | The metabolism of Idelalisib can be increased when combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Idelalisib. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Idelalisib. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Idelalisib. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Idelalisib. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Idelalisib. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Idelalisib. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Idelalisib. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Idelalisib. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Idelalisib. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Idelalisib. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Idelalisib. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Idelalisib. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Idelalisib. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Idelalisib. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Idelalisib. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Idelalisib. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Idelalisib. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Idelalisib. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Idelalisib. |
| Ixabepilone | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Idelalisib. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Idelalisib. |
| Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Idelalisib. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Idelalisib. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Idelalisib. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Idelalisib. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Idelalisib. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Idelalisib. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Idelalisib. |
| Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Idelalisib. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bendamustine is combined with Idelalisib. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Idelalisib. |
| Wortmannin | The risk or severity of adverse effects can be increased when Wortmannin is combined with Idelalisib. |
| Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Idelalisib. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Idelalisib. |
| Teriflunomide | The risk or severity of liver damage can be increased when Idelalisib is combined with Teriflunomide. |